Rapid LVO

by RapidAI (formerly iSchemaView)  · Based in United States → — Clinically deep AI. Beyond the algorithm. Empowering care teams to rapidly, precisely, and confidently manage life-threatening conditions.
Emergency Medicine Neurology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact vendor for pricing.
Regulatory Status Disclosed

Overview

Rapid LVO, developed by RapidAI (formerly iSchemaView), is an advanced AI-powered software solution designed to accelerate the identification of suspected Large Vessel Occlusions (LVOs) in patients undergoing CT angiography (CTA) for acute ischemic stroke. The tool analyzes CTA head images and delivers results and compressed source files to the stroke care team via PACS, email, and dedicated mobile and web apps in as few as 3 minutes. This rapid detection, with reported sensitivity of 96-97% and specificity of 96-98%, helps streamline triage decisions, facilitate faster patient transfers to comprehensive stroke centers, and ultimately improve patient outcomes by reducing time to treatment. Rapid LVO is part of the broader RapidAI platform, which offers a suite of AI tools for neurovascular, cardiac, and vascular conditions, integrating seamlessly into existing hospital workflows and providing critical decision support for physicians across various specialties.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Fast identification of suspected LVOs (as fast as 3 minutes).
  • High sensitivity (96-97%) and specificity (96-98%) for LVO detection.
  • Automated notifications to care team members (PACS, email, mobile app).
  • Streamlines triage and transfer decisions for stroke patients.
  • AI-powered image analysis of CTA head images.
  • 3D reconstruction of vasculature (part of Rapid CTA, likely integrated).
  • Integration with PACS and EMR.
  • Supports various hospital environments and referral networks.
  • Clinically validated platform.
  • Role-based access control.

Use Cases

  • Acute ischemic stroke diagnosis and management.
  • Detection of Large Vessel Occlusions (LVOs).
  • Prioritization of imaging workflow.
  • Facilitating timely patient transfer to comprehensive stroke centers.
  • Improving communication and coordination among stroke care teams.
  • Assisting in treatment decision-making (e.g., thrombectomy eligibility).

What Physicians Need to Know

Stroke Detection Speed
Rapid LVO can quickly detect anterior circulation large vessel occlusion (LVO) with a mean average time of 3 minutes 30 seconds. The RapidAI platform processes CT scans and alerts physicians of suspected LVO in as few as 3 minutes. Rapid NCCT Stroke, which detects suspected intracranial hemorrhage (ICH) and LVO, offers image analysis in less than 3 minutes.
Brain MRI/CT Analysis
RapidAI is an AI-enabled software platform that facilitates the viewing, processing, and analysis of CT imaging, including CT angiography (CTA) scans for LVO detection. The comprehensive stroke evaluation includes identifying LVOs, analyzing salvageable tissue, and managing hemorrhages using AI-based imaging analysis, including perfusion maps. Rapid NCCT Stroke utilizes AI to analyze non-contrast CT (NCCT) images for suspected ICH and LVO. The platform also offers modules like Rapid ASPECTS, Rapid Hypodensity, Rapid CTA, and Rapid Perfusion Imaging for detailed CT analysis.
Large Vessel Occlusion Detection
Rapid LVO is an automated tool for fast and reliable detection of anterior circulation LVO, specifically in intracranial internal carotid artery (ICA) and middle cerebral artery (MCA) M1. It demonstrates high sensitivity (96-98%) and specificity (98%) for LVO detection. The DUEL study showed Rapid LVO detected 33% more LVO-positive cases than a leading competitor (98% sensitivity vs. 74%). Rapid NCCT Stroke is FDA-cleared to detect suspected LVO from non-contrast CT images. The Rapid LMVO module extends detection to ICA, MCA, ACA, Basilar, and PCA.
Triage Prioritization Speed
Rapid LVO accelerates clinical workflow and expedites time to treatment. The system automatically notifies the entire care team within minutes of a scan when an LVO is detected, streamlining communication and accelerating decision-making. Rapid NCCT Stroke delivers triage and prioritization notifications via PACS, email, and the Rapid mobile app, accelerating door-to-imaging and door-to-decision times. Implementation of the Rapid Workflow for Stroke mobile app has significantly reduced intrahospital treatment times, including door-to-groin puncture and door-to-recanalization times.
ASPECTS Score Automation
Rapid ASPECTS provides an automated system for scoring non-contrast CT scans based on the Alberta Stroke Program Early CT Score (ASPECTS). It helps determine thrombectomy eligibility with an automated ASPECT score and quickly visualizes regions of asymmetry and ischemic change. This automation can improve clinician diagnostic accuracy, increase reader reliability, and reduce intra-reader variability, delivering a standardized ASPECT score in less than 2 minutes.
Mobile Notification System
The Rapid Mobile App provides real-time notifications to physicians' mobile devices for new case events. It allows immediate access to Rapid results and source images directly from the app, facilitating faster treatment decisions. The mobile app streamlines workflow, enabling physicians to view, organize, and track cases from multiple sites and communicate securely with stroke teams. Notifications are delivered through PACS, email, and the Rapid mobile app.
Physician Tip

Leverage Rapid LVO's rapid detection capabilities (under 3.5 minutes) and high accuracy to make swift, time-sensitive treatment and transfer decisions for stroke patients. Utilize the automated ASPECTS scoring to quickly assess thrombectomy eligibility and standardize interpretations. The mobile notification system is crucial for real-time team coordination and remote access to critical imaging results, enhancing workflow efficiency and reducing diagnostic delays. Integrate the comprehensive suite of RapidAI tools for a holistic stroke evaluation, including perfusion analysis and hemorrhage detection, to support confident decision-making across the entire patient journey.

RapidAI's platform is designed for seamless integration across various hospital systems, including PACS, email, and mobile applications. It integrates with existing scanners, PACS, worklist prioritization, and reporting systems to streamline workflows. The Rapid Enterprise Platform, supported by the Rapid Edge Cloud, ensures a secure IT infrastructure with both cloud-first and on-premise capabilities, facilitating continuous service and data access.

Details

Category Neurology AI, Radiology & Imaging AI, Triage & ER/ICU AI
Pricing Contact vendor for pricing.
DeploymentCloud-based (Rapid Edge Cloud) and on-premise server options, integrated with PACS.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status Yes. AI-estimated

Rapid LVO (K221248) received FDA clearance on April 29, 2022, as a radiological computer-aided triage and notification software indicated for use in the analysis of CTA head images to flag and communicate suspected positive Large Vessel Occlusion (LVO) findings.
Integrations
EHR Not specified
Specialties Emergency Medicine, Neurology, Radiology

What the Web Says

Rapid LVO, developed by RapidAI, is an AI-powered software designed to assist in the rapid detection of large vessel occlusions (LVOs) and other stroke-related conditions from CT angiography (CTA) scans. It aims to streamline workflow, reduce diagnosis time, and improve communication among healthcare teams, ultimately leading to faster treatment and potentially better patient outcomes. While generally praised for its speed and accuracy, some physicians note its susceptibility to image quality issues and a tendency for false positives.

Overall: Positive

Strengths

  • Rapid and accurate detection of LVOs, intracranial hemorrhage (ICH), and CT perfusion issues.
  • Significantly reduces radiology-report turnaround time.
  • Automates notifications to the entire care team (ER physician, radiologist, neurologist) within minutes of the scan, even before images reach PACS.
  • Outperformed competitor Viz LVO in identifying LVOs and LVO-negative cases in comparative studies.
  • Helps focus radiologist interpretation to specific regions of anatomy.
  • Creates 3D MIPs of the head, reducing post-processing time for other vascular imaging.

Limitations

  • Susceptible to motion and poor contrast boluses, leading to less accurate LVO detection.
  • Can produce a significant number of false positives, potentially leading to 'alarm desensitization' and wasted time for radiologists.
  • Some studies suggest it is less reliable than neuroradiologists in acute LVO detection.
  • Impact on patient harms, mortality, quality of life, length of hospital stay, or healthcare resource implications is uncertain due to limited evidence.
  • Cost-effectiveness is not well-documented or unknown in some reviews.
  • Ethical considerations regarding data privacy, equitable access, and informing patients about AI use.

Based on reviews from: Reddit (r/Radiology, r/emergencymedicine, r/AskDocs), NeurologyLive, Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection (article), RapidAI for Stroke Detection and AI Implementation Review (article/report), A retrospective analysis comparing AIDoc and RAPIDAI in the detection of large vessel occlusions (PMC), RapidAI Review - RapidAI for Stroke Detection: Main Report (NCBI Bookshelf), RapidAI for Stroke Detection: Main Report (Canada's Drug Agency), RapidAI & RedBrick AI (article), accessdata.fda.gov (FDA document), Stroke: Vascular and Interventional Neurology (article), Health AI Register (article), Although u201cunperfectedu201d, AI has the potential to accelerate and synchronise stroke care (article), Viz LVO versus Rapid LVO in detection of large vessel occlusion on CT angiography for acute stroke (PubMed), Impact of an automated large vessel occlusion detection tool on clinical workflow and patient outcomes (PMC), RapidAI (company website), Capterra

Last updated: 2026-07-23

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Rapid LVO

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

RapidAI
RapidAI Reveals Superiority Over Competition in LVO Detection u2013 33% More Cases Identified Than Leading Competitor
A new study, DUEL, demonstrated that Rapid LVO detected 33% more large vessel occlusion (LVO) cases than a leading competitor, Viz LVO, with 98% sensitivity compared to 74%. The study, presented at the International Stroke Conference, also showed Rapid LVO correctly identified 94% of LVO-negative cases.
2025-02
Diagnostic Imaging
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
Research presented at the International Stroke Conference indicated that Rapid LVO AI software detected 33% more LVO cases on CT angiography than Viz LVO AI software in a comparative retrospective study of 1,525 stroke patients. Rapid LVO identified 146 positive LVO cases compared to 110 by Viz LVO.
2025-02
NeurologyLive
RapidAI Outperforms VizAI in Detecting Large Vessel Occlusion | NeurologyLive
A study led by Dr. Harmeet Sachdev found RapidAI software processed over 99% of eligible cases and identified 98% of LVOs, compared to Viz.ai's 90% processing and 74% LVO identification. RapidAI also correctly identified 94% of LVO-negative cases versus 91% for Viz.ai.
2025-02
RapidAI Blog
Beyond Detection: How RapidAI is Redefining Clinical AI with Problem-Solving at Scale
RapidAI CEO Karim Karti emphasized the distinction between AI that identifies problems and AI that solves them, highlighting Rapid LVO's qualification for Medicare's New Technology Add-on Payment in 2020. A February 2025 study showed Rapid LVO detected 33% more LVO cases than Viz.ai.
2025-10
RapidAI
RapidAI Receives FDA Clearance of Rapid LVO
RapidAI announced that Rapid LVO received FDA clearance for detecting suspected Large Vessel Occlusions (LVOs), aiding physicians in faster triage and transfer decisions. The software identifies suspected LVOs in as few as 3 minutes with a sensitivity of 97% and specificity of 96%.
2020-08
Medical Device Network
US FDA clears RapidAI's software for large vessel occlusions detection
The US FDA cleared RapidAI's Rapid LVO software for detecting suspected large vessel occlusions, which assists physicians in quicker triage or transfer decision-making. The software uses a vessel tracker and assesses brain regions with reduced blood vessel density.
2020-08
Medical Product Outsourcing (MPO)
RapidAI's RapidLVO Earns FDA Nod to Spot Large Vessel Occlusions
RapidAI's Rapid LVO received FDA clearance for detecting suspected LVOs, aiming to speed up triage and transfer decisions for stroke patients. The software operates in as few as 3 minutes with high sensitivity and specificity.
2020-08
RapidAI
Identification of anterior circulation large vessel occlusion using Rapid LVO - RapidAI
A retrospective study published in Radiology demonstrated that Rapid LVO can quickly and accurately detect anterior circulation large vessel occlusion (LVO) with a sensitivity of 96% and specificity of 98%. The software achieved a mean detection time of 3 minutes 30 seconds.
2021-06

Videos

Product demos, reviews, and walkthroughs for Rapid LVO.

No videos found. Search YouTube directly

View all on YouTube

Frequently Asked Questions

AI-powered Rapid LVO solutions typically integrate with PACS systems and mobile applications, automatically analyzing CT angiography scans to identify suspected large vessel occlusions. This integration provides real-time alerts to the stroke team, significantly expediting notification and potentially reducing time to treatment for eligible patients.
Most commercially available Rapid LVO AI solutions, such as Rapid LVO and Viz LVO, have received FDA clearance as Class II medical devices for their intended use as decision support tools. These systems are designed with robust security features and data anonymization protocols to ensure HIPAA compliance and protect patient privacy.
The primary alternative is manual interpretation of imaging by neuroradiologists or stroke neurologists. While human interpretation is highly accurate, AI offers rapid, consistent analysis and immediate alerts, potentially reducing radiology CTA report turnaround times and door-to-treatment times, especially at transfer centers or resource-limited sites.
Pricing models often involve subscription fees based on scan volume or per-study charges, with annual costs ranging from $50,000 to $250,000. Medicare offers a New Technology Add-on Payment (NTAP) for AI-based LVO detection, providing up to $1,040 per qualifying case, which can help offset technology costs and drive adoption.
Limitations include potential false positives (ranging from 5-25%) or false negatives, especially in cases with significant artifacts, subtle findings, or atypical anatomy. AI performance can also be lower for smaller strokes, posterior circulation events, or more distal occlusions (e.g., M2-M4 segments), and it should always be used as a decision support tool alongside clinical judgment.
While AI algorithms are continuously improving to process images with artifacts and detect subtle findings, challenging cases still require careful human review. The AI's output should always be interpreted within the full clinical context, as excessive patient motion or inadequate contrast can lead to technically inadequate scans.
Vendors generally provide comprehensive initial training for radiologists, neurologists, and IT staff, often through self-paced online courses, live virtual or onsite sessions, and role-based learning paths. Ongoing technical support, software updates, and educational resources like case studies and quick reference guides are also standard offerings.

Related Tools

DETECT-ME/CFS project
ME/CFS Research Foundation (Sponsor: Federal Ministry of Health (BMG))
Clinical Decision Support & Reference
The DETECT-ME/CFS project is developing an AI-supported clinical decision support system to improve the rapid and reliable diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Neurotrack
Neurotrack
Clinical Decision Support & Reference
Neurotrack is a cognitive care enablement platform that provides clinically validated, FDA class II device assessments and care planning support to identify and manage cognitive decline and dementia earlier and with greater accuracy.
LesionQuant
CorTechs Labs
Neurology AI
LesionQuant, an FDA-approved AI product by CorTechs Labs, is particularly useful for patients with multiple sclerosis. It provides brain structure data and quantifies the number, size, and location of lesions, comparing them to prior studies.
ExcelsiusGPS
Globus Medical
Neurology AI
ExcelsiusGPS™ is the first and only robotic navigation platform on the market that offers a comprehensive approach to spine and cranial procedures, from start to finish. The system enables repeatable and accurate trajectory alignment and navigation for placing screws, interbody implants, and cranial instruments.
Paid
Onera SleepMap
Onera B.V.
Neurology AI
Onera SleepMap is an AI-powered sleep analysis software that processes polysomnography data, part of Onera Health's innovative patch-based system for at-home and in-lab sleep studies. The system aims to make clinical-grade sleep diagnostics more accessible and user-friendly, providing comprehensive data comparable to traditional in-lab PSG.
Per-test pricing
JLK-NCCT
JLK-NCCT
Clinical Decision Support & Reference
JLK-NCCT is an AI software designed to assist in the analysis of non-contrast CT brain scans for the detection of acute ischemic stroke.

See all Neurology AI tools →

More from RapidAI (formerly iSchemaView)

iSchemaView RAPID
RapidAI (formerly iSchemaView)
Neurology AI
RapidAI is an AI-enabled software platform that facilitates the viewing, processing, and analysis of CT and MRI imaging to aid clinicians in assessing patients with suspected stroke, providing automated results for faster, more accurate diagnostic and treatment decisions.
Contact for pricing
Rapid
RapidAI (formerly iSchemaView)
Neurology AI
RapidAI is an AI-driven medical imaging analysis and coordinated care platform that empowers healthcare teams to rapidly, precisely, and confidently manage life-threatening conditions, especially acute stroke, through advanced CT and MRI image processing.
Contact for pricing
Rapid CTA 360
RapidAI (formerly iSchemaView)
Neurology AI
Rapid CTA 360 by RapidAI (formerly iSchemaView) is an AI-powered imaging solution providing automated 3D CTA reconstructions for rapid and precise stroke diagnosis and treatment planning, enhancing visibility of occlusions and collateral flow.
Contact vendor for pricing
Rapid PE Triage and Notification (PETN)
RapidAI (formerly iSchemaView)
Cardiology AI
Rapid PE Triage and Notification (PETN) by RapidAI is an AI-powered software that analyzes CTPA images to rapidly identify and notify clinicians of suspected central pulmonary embolisms, streamlining workflow and accelerating patient care pathways.
Contact for pricing

View company profile →

Suggest an Edit → | Last Verified: 2026-04-21 | First Added: 2026-04-21
AI Tool Finder
AI-powered search. Results may not be comprehensive.